- Haleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands, including Sensodyne, Voltaren, Panadol and Centrum
- Business is on track to demerge and list as a new company in mid-2022
GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon.
Haleon (pronounced “Hay-Lee-On”) is inspired by the merging of the words ‘Hale’, which is an old English word that means ‘in good health’ and Leon, which is associated with the word ‘strength’. The new brand identity was developed with input from employees, healthcare practitioners and consumers and will be deployed in more than 100 markets around the world where the business operates.
The creation of Haleon results from a series of successful investments and strategic changes to GSK’s consumer health business over the last 8 years, including integrations of the consumer product portfolios from Novartis and Pfizer. It is now a highly valuable and focused global business generating annual sales of approximately £10 billion[i].
As a standalone company, Haleon will be a new world-leader in consumer healthcare, offering a compelling proposition – to bring deep human understanding together with trusted science – to deliver better everyday health with humanity.
Brian McNamara, Chief Executive Officer Designate, Haleon, said: “Introducing Haleon to the world marks another step in our journey to become a new, standalone company. Our name is grounded in our purpose to deliver better everyday health with humanity and to be a world-leader in consumer healthcare. We are on track to launch Haleon in mid-2022 and our business momentum is strong. We look forward to updating investors and analysts more on this at our capital markets event at the end of February.”
Emma Walmsley, Chief Executive Officer, GSK, said: “Haleon brings to life years of hard work by many outstanding people to build this new company purely dedicated to everyday health. Haleon has enormous potential to improve health and wellbeing across the world with strong prospects for growth, and through listing will unlock significant value for GSK shareholders.”
In Ireland, GSK Consumer Healthcare employs 930 people. 900 are located in Dungarvan, while a 30 strong sales and commercial team based in Dublin manage the Consumer Healthcare portfolio of products and sell to customers in Ireland. Dungarvan is one of the largest manufacturing sites in GSK’s Consumer Health network.
Dave Barrett, Country Manager of GSK Consumer Healthcare in Ireland, said: “I am delighted to drive this exciting chapter in our company history together with the fantastic Ireland team. We will continue to be an important partner for consumers, customers and healthcare practitioners to ensure Haleon delivers better everyday health with humanity. We are very proud of our market leading and globally trusted brands, including household names like Sensodyne, Corsodyl, Centrum, and of course Panadol which is made in Ireland.
Over the past forty years, our Panadol facility in Dungarvan has become one of the largest manufacturing sites in GSK’s Consumer Health network, producing both ‘over the counter’ pain relief and oral healthcare products for global supply to over 70 markets. We are well positioned to grow our business in Ireland over the coming years, and we look forward to keeping our teams in Dublin and Waterford updated every step of the way.”
Conor Tolan, Site Director of GSK Dungarvan in Waterford, said: “2022 promises to be a landmark year for our dedicated 900 strong team in Dungarvan. As a focused Consumer Healthcare business, we will continue to supply the same portfolio of trusted global brands including Panadol and Poligrip and look forward to launching future innovations that will enable us to service even more customers and grow our business to ensure that Haleon delivers better everyday health with humanity for consumers right across the world. We have a very exciting road ahead of us.”
Haleon will have a world-class portfolio of category-leading global brands, including Sensodyne, Voltaren, Panadol and Centrum. Its brands are trusted by healthcare professionals, customers and people worldwide to improve the health and wellbeing of individuals and their communities. Demand from the £150 billion consumer healthcare sector is strong, reflecting an increased focus on health and wellness, significant demand from an ageing population and emerging middle-class, and unmet consumer needs. The business is therefore well-positioned to deliver human health impact and to sustainably grow ahead of the market in the years to come.
The new name was announced as part of a global celebration for all of the people working in GSK Consumer Healthcare earlier today. Employees from around the world had the opportunity to engage with the new name and brand identity which seeks to bring to life the company’s purpose and growth ambitions.
The name was also announced in advance of GSK hosting a Consumer Healthcare Capital Markets Day for investors and analysts on Monday 28 February, to provide details on the overall strategy, capabilities and operations of Haleon, including detailed financial information and growth ambitions of the business. For prospective investors, Haleon will offer attractive organic sales growth, operating margin expansion and consistent high cash generation.
[i] Sales in FY2021 £9.6 billion, including Brands divested/under review; £9.5bn continuing sales
